VITASPRING BIOMEDICAL Files 8-K: CEO Resigns; New CEO & Chairman Appointed

What Happened
VITASPRING BIOMEDICAL Co. Ltd. filed an 8‑K announcing that Dr. Ssu‑Chuan Lai resigned as Chairperson, Chief Executive Officer, President, Chief Financial Officer, Secretary and as a director effective 11:58 p.m. Pacific Time on September 7, 2026. Prior to her resignation, as sole director then in office, Dr. Lai appointed Jing‑Zhou Chen to serve as CEO, President, CFO and Secretary (effective 11:57 p.m. PT on September 7, 2026) and elected Shao‑Hsiang Shih as a director and appointed him Chairman of the Board (elected 11:56 p.m. PT; appointed Chairman 11:57 p.m. PT on September 7, 2026). The filing states Dr. Lai’s resignation was not due to any disagreement with the company.

Key Details

• Resignation: Ssu‑Chuan Lai resigned all officer roles and her board seat effective Sept 7, 2026 at 11:58 p.m. PT; resignation letter is filed as Exhibit 17.1.
• New officers: Jing‑Zhou Chen (age 40) named CEO, President, CFO and Secretary; no employment agreement or compensation yet in place.
• New chairman/director: Shao‑Hsiang Shih (age 54) elected director and appointed Chairman; no compensation yet in place.
• Backgrounds: Chen’s recent roles include founder/CEO of Dream Born Co., Ltd. (since Mar 2025) and prior management/engineering roles; Shih has long experience in administrative/education management at Century Publishing and related entities.
• Governance notes: The Board had been a single director at the time of these actions; the company does not maintain standing board committees and has authorized indemnification and advancement of expenses for Chen and Shih (no indemnification agreements executed yet).
• No related-party issues: The filing discloses no family relationships, no arrangements leading to the appointments, and no reportable related-party transactions under Item 404(a) of Regulation S‑K.

Why It Matters
This 8‑K reports immediate leadership turnover at VITASPRING with its longtime principal officer stepping down and new individuals assuming the company’s top executive and board roles. For investors, leadership changes can affect strategy, operations and investor communications; here, the company notes there are no employment contracts or planned compensation for the new appointees yet, and indemnification protections were authorized but not finalized. Investors should note the precise effective dates and that the board composition and governance (no standing committees) have changed; monitor future filings for any employment agreements, compensation decisions, or additional governance updates.